16 September 2026 editorial review · Item
T1DRA (Type 1 Diabetes Risk in Adults): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
-
Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. -
Claim check: T1DRA official site search-index text supports free UK age 18–70 home testing and consent route; direct homepage fetch failed (index 2 months old). Corrected claim that US adult route is T1Detect and no other country adult route; ASK/Type1Screen are verified alternatives. Current direct recruitment confirmation remains limited.
-
Primary publication/regulatory sources checked or consulted: teplizumab-to-delay-the-onset-of-type-1-diabetes-recommended; dom.70569.
-
Programme/sponsor/conference source boundary: T1DRA — Type 1 Diabetes Risk in Adults (official study site) (official study programme).
-
Retrieval limit (not a falsity finding): https://t1dra.bristol.ac.uk/.
-
Follow-up access check: direct homepage timed out and consent page returned 502; indexed eligibility/consent/news pages were two to four months old. Public summary, status, access score and availability labels now say current recruitment is unconfirmed. Removed unsupported worldwide-exclusive screening claims and identified ASK/Type1Screen alternatives. Study consent page, eligibility and news were available through indexed text only.